Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study

Recruiting Observational Study
Schistosomiasis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
24 Months – 59 Months
Sex
Any
Study type
Observational
Participants needed
18,500 (estimated)
Sponsor
Peter Steinmann · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The proposed small-scale pilot studies are public health intervention studies implemented through established routine programs and services in the frame of the mass drug administration (MDA) campaigns in Côte d'Ivoire, Kenya and Uganda. In each country two most promising health intervention platforms were selected for pilot distribution of arpraziquantel 150mg (arPZQ). The aim of the small-scale …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* Living in the designated implementation area since at least 6 months * Aged between 24 - 59 months * Informed consent available * No acute or chronic illness and/or inability to take oral medication * No reported history of seizures * No known allergic response to praziquantel
Contacts

Peter Steinmann, PhD PD

+41 61 284 82 18

peter.steinmann@swisstph.ch

CONTACT

Nora Monnier, Dr. med.

+41 61 284 82 29

nora.monnier@swisstph.ch

CONTACT